Sedativní účinek nízkých dávek risperidonu u pacientů s generalizovanou úzkostnou poruchou a riziko lékových interakcí

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F06%3A00000614" target="_blank" >RIV/00023752:_____/06:00000614 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/06:00001568

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions

Popis výsledku v původním jazyce

Based on their results, Brawman-Mintzer et al. 2005 suggest that adjunctive risperidone at low doses may represent a useful tool in the management of symptomatic GAD patients. They found statistically significant improvements in core anxiety symptoms, asdemonstrated by greater reduction in HAM-A total scores (p=.034) and HAM-A psychic anxiety factor scores (p=.047) compared to placebo. Brawman-Mintzer et al. 2005 also conclude that between-group differences in reported adverse events were not clinically significant. However, scrutinizing published data, a statistically significant difference can be detected: more risperidone-treated patients reported somnolence (9 out of 19 patients) over placebo group (3 of 20 patients); Fisher`s exact, two tailed p=.047. This statistical difference can be arguably of clinical relevance, since risperidone-induced calming effects may be in fact attributed to sedation rather than to specific anxiolytic effects. Somnolence in low doses risperidone group

Název v anglickém jazyce

Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions

Popis výsledku anglicky

Based on their results, Brawman-Mintzer et al. 2005 suggest that adjunctive risperidone at low doses may represent a useful tool in the management of symptomatic GAD patients. They found statistically significant improvements in core anxiety symptoms, asdemonstrated by greater reduction in HAM-A total scores (p=.034) and HAM-A psychic anxiety factor scores (p=.047) compared to placebo. Brawman-Mintzer et al. 2005 also conclude that between-group differences in reported adverse events were not clinically significant. However, scrutinizing published data, a statistically significant difference can be detected: more risperidone-treated patients reported somnolence (9 out of 19 patients) over placebo group (3 of 20 patients); Fisher`s exact, two tailed p=.047. This statistical difference can be arguably of clinical relevance, since risperidone-induced calming effects may be in fact attributed to sedation rather than to specific anxiolytic effects. Somnolence in low doses risperidone group

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Psychiatry

ISSN

0160-6689

e-ISSN

—

Svazek periodika

67

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—